Exciting News: We’re Partnering with Avicanna Develop and Make Medical Cannabis Education Programs Available to our Members
January 31st, 2025, Toronto
We, Nurse Practitioners’ Association of Ontario (“NPAO”), are thrilled to announce our partnership with Toronto-based biopharmaceutical company, Avicanna, to develop and provide accessible, high-quality educational services to empower our members and community with critical knowledge and resources about medical cannabis. Avicanna will be sponsoring two educational scholarships and various educational bursaries. Additionally, the company’s Medical Affairs team will work with the NPAO to create educational programs covering a range of topics.
“We’re excited to partner with Avicanna to advance medical cannabis education for our members. This collaboration will empower nurse practitioners with the knowledge, resources, and evidence-based insights needed to confidently support innovative patient care and navigate the evolving landscape of medical cannabis.” stated Dr. NP Michelle Acorn, CEO of NPAO.
“We are delighted to collaborate with NPAO in its mission to expand the body of knowledge surrounding medical cannabis and to support its members in delivering accessible medical cannabis education programs. This partnership reflects our steadfast commitment to advancing scientific understanding and contributing to the evolving landscape of medical cannabis in Canada.” stated Dr. Karolina Urban, EVP of Medical Affairs at Avicanna.
About the NPAO
The NPAO is a professional organization representing nurse practitioners working in all levels of healthcare including primary, secondary and tertiary care and nurse practitioner-led clinics across Ontario.
About Avicanna:
Avicanna is an international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting its commercial stage business pillars.
- Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and also expanding into new international markets.
- Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
- Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based drug candidates aim to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
